- Home
- PLX vs GECC Comparison
PLX vs GECC Comparison
Compare PLX & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- GECC
- Stock Information
- Founded
- PLX 1993
- GECC 2016
- Country
- PLX United States
- GECC United States
- Employees
- PLX N/A
- GECC N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- GECC Finance: Consumer Services
- Sector
- PLX Health Care
- GECC Finance
- Exchange
- PLX Nasdaq
- GECC Nasdaq
- Market Cap
- PLX 122.6M
- GECC 122.4M
- IPO Year
- PLX 1998
- GECC N/A
- Fundamental
- Price
- PLX $1.40
- GECC $10.50
- Analyst Decision
- PLX Strong Buy
- GECC
- Analyst Count
- PLX 1
- GECC 0
- Target Price
- PLX $15.00
- GECC N/A
- AVG Volume (30 Days)
- PLX 640.7K
- GECC 20.2K
- Earning Date
- PLX 08-13-2025
- GECC 07-31-2025
- Dividend Yield
- PLX N/A
- GECC 14.07%
- EPS Growth
- PLX N/A
- GECC N/A
- EPS
- PLX 0.05
- GECC 0.42
- Revenue
- PLX $59,764,000.00
- GECC $42,909,000.00
- Revenue This Year
- PLX $65.02
- GECC $32.54
- Revenue Next Year
- PLX $57.34
- GECC N/A
- P/E Ratio
- PLX $28.96
- GECC $25.06
- Revenue Growth
- PLX 0.18
- GECC 18.13
- 52 Week Low
- PLX $0.82
- GECC $8.87
- 52 Week High
- PLX $3.10
- GECC $11.39
- Technical
- Relative Strength Index (RSI)
- PLX 30.38
- GECC 46.09
- Support Level
- PLX $1.52
- GECC $10.90
- Resistance Level
- PLX $1.65
- GECC $10.62
- Average True Range (ATR)
- PLX 0.08
- GECC 0.22
- MACD
- PLX 0.02
- GECC -0.06
- Stochastic Oscillator
- PLX 17.19
- GECC 25.53
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.